GENinCode (LSE:GENI) FCF Yield % : -59.83 (As of Jun. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, GENinCode's Trailing 12-Month Free Cash Flow is £-7.54 Mil, and Market Cap is £12.61 Mil. Therefore, GENinCode's FCF Yield % for today is -59.83%.

The historical rank and industry rank for GENinCode's FCF Yield % or its related term are showing as below:

LSE:GENI' s FCF Yield % Range Over the Past 10 Years
Min: -224.95 Med: -36.61 Max: -2.54
Current: -59.83

During the past 5 years, the highest FCF Yield % of GENinCode was -2.54%. The lowest was -224.95%. And the median was -36.61%.

LSE:GENI's FCF Yield % is ranked worse than
87.07% of 232 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.345 vs LSE:GENI: -59.83

GENinCode's FCF Margin % for the quarter that ended in Dec. 2023 was -250.91%.

GENinCode FCF Yield % Historical Data

The historical data trend for GENinCode's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode FCF Yield % Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-10.40

-61.60

-149.97

GENinCode Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial			-14.17	-22.59	-67.82	-78.41	-120.71

Competitive Comparison of GENinCode's FCF Yield %

For the Diagnostics & Research subindustry, GENinCode's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode's FCF Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's FCF Yield % distribution charts can be found below:

* The bar in red indicates where GENinCode's FCF Yield % falls into.

GENinCode FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

GENinCode's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-7.544	/	5.03038725
	=	-149.97%

GENinCode's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-3.036	*	2	/	5.03038725
	=	-120.71%

GENinCode FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

GENinCode FCF Yield % Related Terms

Thank you for viewing the detailed overview of GENinCode's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode (LSE:GENI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.